Business Description
Tyra Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US90240B1061
Total Employee Number:
87Description
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 67.31 | |||||
Equity-to-Asset | 0.94 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -16.6 | |||||
3-Year EPS without NRI Growth Rate | -15 | |||||
3-Year FCF Growth Rate | -9.6 | |||||
3-Year Book Growth Rate | -7.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -13.6 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 68.28 | |||||
9-Day RSI | 63.79 | |||||
14-Day RSI | 58.69 | |||||
3-1 Month Momentum % | -27.91 | |||||
6-1 Month Momentum % | -13.27 | |||||
12-1 Month Momentum % | 148.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 20.49 | |||||
Quick Ratio | 20.49 | |||||
Cash Ratio | 19.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.2 | |||||
Shareholder Yield % | -7.51 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -42.21 | |||||
ROA % | -39.45 | |||||
ROIC % | -746.2 | |||||
3-Year ROIIC % | -897.8 | |||||
ROC (Joel Greenblatt) % | -2024.62 | |||||
ROCE % | -45.22 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 5.02 | |||||
Price-to-Tangible-Book | 5.02 | |||||
EV-to-EBIT | -10.99 | |||||
EV-to-Forward-EBIT | -8.79 | |||||
EV-to-EBITDA | -11.03 | |||||
EV-to-Forward-EBITDA | -8.88 | |||||
EV-to-FCF | -15.32 | |||||
| Price-to-Net-Current-Asset-Value | 5.27 | |||||
| Price-to-Net-Cash | 5.42 | |||||
Earnings Yield (Greenblatt) % | -9.1 | |||||
FCF Yield % | -5.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TYRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tyra Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.18 | ||
| Beta | 0.6042 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 1.03 | ||
| Volatility % | 46.58 | ||
| 14-Day RSI | 58.69 | ||
| 14-Day ATR ($) | 1.856652 | ||
| 20-Day SMA ($) | 30.2655 | ||
| 12-1 Month Momentum % | 148.24 | ||
| 52-Week Range ($) | 9.96 - 40.65 | ||
| Shares Outstanding (Mil) | 59.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tyra Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tyra Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 117 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 34 days | ||
| Jefferies Global Healthcare Conference | 2026-06-03 15:45 | 28.66 (-4.53%) | ||
| General meeting for 2026 | 2026-05-28 10:00 | 33.17 (-0.60%) | ||
| TD Cowen\'s 7 Annual Oncology Innovation Summit: Insights for ASCO & EHA | 2026-05-26 14:00 | 32.47 (-1.78%) | ||
| Guidance call for 2026 | 2026-05-13 10:40 | 34.87 (+3.17%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 34.87 (+3.17%) | ||
| Barclays 28 Annual Global Healthcare Conference | 2026-03-10 | 33.75 (-2.91%) | ||
| Guidance call for 2026 | 2026-03-09 | 35.04 (+1.62%) | ||
| Leerink Global Healthcare Conference | 2026-03-08 | 35.04 (+1.62%) |
Show
Entries
Tyra Biosciences Inc Frequently Asked Questions
What is Tyra Biosciences Inc(TYRA)'s stock price today?
The current price of TYRA is $32.75. The 52 week high of TYRA is $40.65 and 52 week low is $9.96.
When is next earnings date of Tyra Biosciences Inc(TYRA)?
The next earnings date of Tyra Biosciences Inc(TYRA) is 2026-08-14 Est..
Does Tyra Biosciences Inc(TYRA) pay dividends? If so, how much?
Tyra Biosciences Inc(TYRA) does not pay dividend.
Guru Commentaries on NAS:TYRA
No articles.
Press Release
Articles on Tyra Biosciences Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers